SCHEMBL2853583

SCHEMBL2853583

N#Cc1ccc([N+](=O)[O-])cc1C(F)(F)F

nearest known ligand 0.54

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
VCAM1 P19320 2/20 0.54
PTGES O14684 1/20 0.52
AR P10275 11/20 0.50
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
PDE7A Q13946 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15320658 0.87 VCAM1 (0.51) VCAM1PTGESARALDH1A1LMNA
SCHEMBL3522985 0.83 VCAM1 (0.54) VCAM1ARALDH1A1LMNA
SCHEMBL23832425 0.80 AR (0.51) PTGESAR
SCHEMBL30104270 0.80 AR (0.51) PTGESAR
SCHEMBL2814868 0.80 PDE7A (0.44) VCAM1PTGESARALDH1A1LMNA
Water SCHEMBL27993079 0.79 AR (0.52) ARALDH1A1PDE7A
SCHEMBL11063382 0.78 AR (0.47) VCAM1ARALDH1A1PDE7A
SCHEMBL1999857 0.78 PDE7A (0.54) ARALDH1A1LMNAPDE7A
SCHEMBL73860 0.78 VCAM1 (0.70) VCAM1ALDH1A1LMNA
SCHEMBL11088786 0.78 SLC22A12 (0.51) VCAM1PTGESARALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102875414-A Preparation method of 4-amino-2-trifluoromethyl cyanophenyl CHANGZHOU WATSON FINE CHEMICALS CO LTD 2013-01-16 CN claimed
CN-118666714-A Purification method of bicalutamide intermediate 江西金丰药业有限公司 2024-09-20 CN disclosed
US-11319282-B2 Diamine compound and method for producing same LG CHEM, LTD. (KR) 2022-05-03 US disclosed
CN-109415301-B Diamine compound and method for producing same 株式会社LG化学 2021-08-17 CN disclosed
EP-2853532-B1 1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III INST FARMAKOLOGII POLSKIEJ AKADEMII NAUK (PL) 2020-12-09 EP disclosed
EP-3696165-A1 PROCESS FOR THE PREPARATION OF 4-HALOPHENOXY-2-TRIFLUOROMETHYL BENZONITRILE BASF Agro B.V. (NL) 2020-08-19 EP disclosed
EP-3696159-A1 PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENOXYPHENYL KETONES BASF Agro B.V. (NL) 2020-08-19 EP disclosed
EP-3696164-A1 PROCESS FOR THE PREPARATION OF 4-NITRO-2-(TRIFLUOROMETHYL)-BENZONITRILE BASF Agro B.V. (NL) 2020-08-19 EP disclosed
EP-3696164-A1 PROCESS FOR THE PREPARATION OF 4-NITRO-2-(TRIFLUOROMETHYL)-BENZONITRILE BASF Agro B.V. (NL) 2020-08-19 EP disclosed
US-20190292138-A1 DIAMINE COMPOUND AND METHOD FOR PRODUCING SAME LG CHEM, LTD. (KR) 2019-09-26 US disclosed
WO-2009068552-A1 PIPERAZINYL-SULFONAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF GPR38 RECEPTOR MEDIATED DISEASES GLAXO GROUP LIMITED (GB) 2009-06-04 WO disclosed
US-20040077729-A1 New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-22 US disclosed
WO-2004013115-A2 CARBOXAMIDES, PRODUCTION AND USE THEREOF AS MEDICAMENTS____ BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-02-12 WO disclosed
EP-0377112-B1 Quinoxaline compounds and their preparation and use NOVO NORDISK AS (DK) 1994-08-24 EP disclosed
US-5187167-A Antitumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-16 US disclosed
US-5081124-A Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-14 US disclosed
EP-0239362-B1 ANTI-TUMOR AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-12-04 EP disclosed
US-5061706-A 2,3-QUINOXALINEDIONES FOR USE AS NEUROLEPTICS NOVO NORDISK A/S (DK) 1991-10-29 US disclosed
EP-0377112-A1 Quinoxaline compounds and their preparation and use NOVO NORDISK A/S (DK) 1990-07-11 EP disclosed
EP-0239362-A2 Anti-tumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292138-A1 DIAMINE COMPOUND AND METHOD FOR PRODUCING SAME DDC, CAD, AOC1 VCAM1 1345/4885PTGES 1747/4885AR 3530/4885
US-20040077729-A1 New carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions F2, F11, F12 VCAM1 947/4885PTGES 899/4885AR 3477/4885
US-11319282-B2 Diamine compound and method for producing same DDC, CAD, AOC1 VCAM1 1345/4885PTGES 1747/4885AR 3530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.